{"mainPropery":{"diseaseId":7193,"diseaseName":"Neurofibromatosis type 2","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/7193/neurofibromatosis-type-2","synonyms":["NF2","Neurofibromatosis central type","Acoustic schwannomas bilateral","Bilateral acoustic neurofibromatosis","Acoustic neurinoma bilateral","Neurofibromatosis type II"],"synonyms-with-source":[{"name":"NF2"},{"name":"Neurofibromatosis central type"},{"name":"Acoustic schwannomas bilateral"},{"name":"Bilateral acoustic neurofibromatosis"},{"name":"Acoustic neurinoma bilateral"},{"name":"Neurofibromatosis type II"}],"identifiers":[{"identifierType":"OMIM","identifierId":"101000"},{"identifierType":"ORPHANET","identifierId":"637"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":19,"diseaseTypeName":"Ear, Nose, and Throat Diseases","source":"Orphanet"},{"diseaseTypeId":9,"diseaseTypeName":"Eye diseases"},{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases","source":"Orphanet"},{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":15,"resourceName":"Nerve Tumours UK","abbreviation":"","address1":"1st Floor  ","address2":"44 Coombe Lane","address3":"","address4":"","address5":"","city":" London","state":"","zip":"SW20 0LA","country":"United Kingdom","phone":"44(0)208 439 1234","tty":"","tollFree":"07939 046 030 (Helpline)","fax":"","email":"info@nervetumours.org.uk","url":"https://nervetumours.org.uk","freeText":""},{"resourceID":16,"resourceName":"Children's Tumor Foundation","abbreviation":"CTF","address1":"120 Wall Street, 16th floor","address2":"","address3":"","address4":"","address5":"","city":"New York","state":"NY","zip":"10005-3904","country":"United States","phone":"+1-212-344-6633","tty":"","tollFree":"1-800-323-7938","fax":"+1-212-747-0004","email":"info@ctf.org","url":"https://www.ctf.org/","freeText":""},{"resourceID":33,"resourceName":"Neurofibromatosis Network","abbreviation":"","address1":"213 S. Wheaton Ave.","address2":"","address3":"","address4":"","address5":"","city":"Wheaton","state":"IL","zip":"60187","country":"United States","phone":"+1-630-510-1115","tty":"","tollFree":"1-800-942-6825","fax":"+1-630-510-8505","email":"admin@nfnetwork.org","url":"https://www.nfnetwork.org/","freeText":""},{"resourceID":34,"resourceName":"Tumour Foundation of BC","abbreviation":"","address1":"19172 Fourth Avenue PO","address2":"","address3":"","address4":"","address5":"","city":"Vancouver, BC","state":"","zip":"V6K 4R8","country":"Canada","phone":"","tty":"","tollFree":"1-800-385-2263","fax":"","email":"info@tumourfoundation.ca","url":"https://www.tumourfoundation.ca","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/101000' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed?term=Neurofibromatosis%20type%202%5Btitle%5D%20OR%20Neurofibromatosis%202%5Btitle%5D%20AND%20hasabstract%5Btext%5D&cmd=DetailsSearch' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Neurofibromatosis type 2. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Neurofibromatosis+type+2%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Neurofibromatosis type 2. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition=neurofibromatosistype2' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Neurofibromatosis type 2. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":176,"resourceId":16,"resourceName":"Children's Tumor Foundation","descriptionText":"The Children's Tumor Foundation, which advocates for research into neurofibromatosis (NF), launched an <a href='http://nfregistry.org/ ' target='_blank'>NF Registry</a> in 2012. The purpose of this registry is to find people who may be eligible for clinical trials or other research studies being conducted in the field of neurofibromatosis and to determine the commonality of specific NF characteristics. <br />","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"},{"id":659,"resourceId":1371,"resourceName":"Neurofibromatosis Find a Doctor","descriptionText":"The <a href='https://www.nfnetwork.org//understand-nf/find-doctor/' target='_blank'>Neurofibromatosis Network</a> provides a tool for locating a neurofibromatosis specialist in your area. Click on Neurofibromatosis Network to access the tool.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C0027832/' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='https://rarediseases.org/rare-diseases/neurofibromatosis-2/' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='http://www.nlm.nih.gov/medlineplus/ency/article/000795.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1530,"resourceId":2161,"resourceName":"National Institute of Neurological Disorders and Stroke (NINDS)","descriptionText":"The <a href='https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Neurofibromatosis-Fact-Sheet' target='_blank'>National Institute of Neurological Disorders and Stroke</a> (NINDS) collects and disseminates research information related to neurological disorders. Click on the link to view information on&nbsp;this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/1178283-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=637' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='https://www.ncbi.nlm.nih.gov/books/NBK1201/' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1538,"resourceId":2169,"resourceName":"MeSH®","descriptionText":"<a href='http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?mode=&index=15604&view=expanded' target='_blank'>MeSH®</a> (Medical Subject Headings) is a terminology tool used by the National Library of Medicine. Click on the link to view information on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1542,"resourceId":2170,"resourceName":"RePORTER","descriptionText":"The <a href='http://projectreporter.nih.gov/reporter.cfm' target='_blank'>Research Portfolio Online Reporting Tool (RePORT)</a> provides access to reports, data, and analyses of research activities at the National Institutes of Health (NIH), including information on NIH expenditures and the results of NIH-supported research.  Although these projects may not conduct studies on humans, you may want to contact the investigators to learn more. To search for studies, enter the disease name in the \"Text Search\" box.  Then click \"Submit Query\".","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1549,"resourceId":2177,"resourceName":"National Human Genome Research Institute","descriptionText":"The <a href='http://www.genome.gov/14514225' target='_blank'>National Human Genome Research Institute's</a> (NHGRI) website has an information page on this topic. NHGRI is part of the National Institutes of Health and supports research on the structure and function of the human genome and its role in health and disease.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1550,"resourceId":2178,"resourceName":"DermNet New Zealand","descriptionText":"<a href='http://dermnetnz.org/systemic/neurofibromatosis.html' target='_blank'>DermNet NZ</a> is an online resource about skin diseases developed by the New Zealand Dermatological Society Incorporated. DermNet NZ provides information about this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1705,"resourceId":2846,"resourceName":"Project OrphanAnesthesia","descriptionText":"<a href='http://www.orphananesthesia.eu/en/rare-diseases/published-guidelines/cat_view/61-rare-diseases/60-published-guidelines/114-neurofibromatosis-type-2.html' target='_blank'>Project OrphanAnesthesia</a> is a project whose aim is to create peer-reviewed, readily accessible guidelines for patients with rare diseases and for the anesthesiologists caring for them. The project is a collaborative effort of the German Society of Anesthesiology and Intensive Care, Orphanet, the European Society of Pediatric Anesthesia, anesthetists and rare disease experts with the aim to contribute to patient safety.","resourceClassificationName":"Treatment","resourceClassificationSectionName":"Management Guidelines"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:101000' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2722,"resourceId":4053,"resourceName":"Patient Registry","descriptionText":"A registry supports research by collecting of information about patients that share something in common, such as being diagnosed with Neurofibromatosis type 2. The type of data collected can vary from registry to registry and is based on the goals and purpose of that registry. Some registries collect contact information while others collect more detailed medical information. <a href=\"https://www.nih.gov/health-information/nih-clinical-research-trials-you/list-registries\" target=\"_blank\">Learn more about registries</a>.<br />\r\n<br />\r\nRegistries for&nbsp;Neurofibromatosis type 2:<br />\r\n<a href='https://nfregistry.patientcrossroads.org/' target='_blank'>NF Registry</a><br />&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"}],"overviewQuestion":{"questionId":1932,"questionText":"What is neurofibromatosis type 2?","answerText":"<strong>Neurofibromatosis type 2 (NF2)</strong> is a disorder characterized by the growth of noncancerous tumors of the nervous system. Childhood symptoms include skin growths and eye findings. Almost all people with NF2 develop&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000778.htm\" target=\"_blank\">vestibular schwannomas</a>&nbsp;affecting both ears by age 30. Other tumors of the central nervous system (the brain and spinal cord), skin and eye are also common. The signs and symptoms vary from person to person. The severity depends on the size, location, and number of tumors. NF2 is caused by changes (<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>) in the <em><a href=\"http://ghr.nlm.nih.gov/gene/NF2\" target=\"_blank\">NF2</a></em> gene and is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm\" target=\"_blank\">autosomal dominant</a> manner. It is diagnosed based on a clinical examination and the symptoms. Genetic testing may be helpful.&nbsp;The treatment is based on managing the signs and symptoms and may include surgery and medications.[9354][15593][15591]","dateModified":"2020-05-26T00:00:00"},"basicQuestions":[{"questionId":9140,"questionText":"What are the signs and symptoms of neurofibromatosis type 2?","answerText":"The following list includes the most common signs and symptoms in people with Neurofibromatosis type 2 (NF2). These features may be different from person to person. Some people may have more symptoms than others and symptoms can range from mild to severe. This list does not include every symptom or feature that has been described in this condition.<br />\r\n<br />\r\nSigns and symptoms may include:[9354][15593]<br />\r\n<ul>\r\n    <li>Benign tumors along the nerves going from the inner ear to the brain (<a href=\"https://medlineplus.gov/acousticneuroma.html\" target=\"_blank\">vestibular schwannomas</a>)\r\n    <ul>\r\n        <li>Ringing in the ear</li>\r\n        <li>Hearing loss</li>\r\n        <li>Balance problems</li>\r\n    </ul>\r\n    </li>\r\n    <li>Benign tumors of the central nervous system (<a href=\"https://www.mayoclinic.org/diseases-conditions/meningioma/symptoms-causes/syc-20355643?p=1\" target=\"_blank\">meningiomas</a>)\r\n    <ul>\r\n        <li>Muscle weakness or numbness</li>\r\n        <li>Dizziness</li>\r\n        <li><a href=\"https://medlineplus.gov/seizures.html\" target=\"_blank\">Seizures</a></li>\r\n    </ul>\r\n    </li>\r\n    <li>Retinal tumors (hamartomas)</li>\r\n    <li>Clouding of the lens (<a href=\"https://medlineplus.gov/cataract.html\" target=\"_blank\">cataracts</a>)</li>\r\n    <li>Skin plaques</li>\r\n</ul>\r\nChildren with NF2 may develop plaque-like lesions of the skin, eye findings including cataracts and retina changes, and nerve damage. By age 30, most individuals with NF2 develop <a href=\"https://medlineplus.gov/acousticneuroma.html\" target=\"_blank\">vestibular schwannomas</a> which cause ringing in the ears, dizziness and balance problems. Other symptoms that may develop include central nervous system tumors such as schwannomas and meningiomas. The severity of NF2 depends on the size and number of tumors that occur.[9354][15593][15594]","dateModified":"2020-05-26T00:00:00","resourceClassificationName":"Symptoms","references":[{"referenceId":9354,"authors":"Evans DG","articleTitle":"Neurofibromatosis 2","bookWebsiteJournalTitle":"GeneReviews","date":"Updated March 15, 2018","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK1201/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":15593,"authors":"Ardern-Holmes S, Fisher G, North K","articleTitle":"Neurofibromatosis type 2: Presentation, Major Complications, and Management, with a focus on the pediatric age group","bookWebsiteJournalTitle":"J Child Neurol","date":"Jan 2017","volume":"32(1)","pages":"9-22","url":"https://www.ncbi.nlm.nih.gov/27655473","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":15594,"authors":"Evans DG","articleTitle":"Neurofibromatosis type 2","bookWebsiteJournalTitle":"Handb Clin Neurol","date":"2015","volume":"132","pages":"87-96","url":"https://pubmed.ncbi.nlm.nih.gov/26564072","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":4329,"questionText":"What causes neurofibromatosis type 2?","answerText":"Neurofibromatosis type 2 is caused by a&nbsp;<em><a href=\"http://ghr.nlm.nih.gov/gene/NF2\" target=\"_blank\">NF2</a></em> gene that is not working correctly.[9354] Genetic changes known as <a href=\"https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/genetic-variant\" target=\"_blank\">DNA variants</a> can impact how genes work. Pathogenic variants are responsible for making genes work incorrectly or sometimes, not at all.","dateModified":"2020-05-26T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":9354,"authors":"Evans DG","articleTitle":"Neurofibromatosis 2","bookWebsiteJournalTitle":"GeneReviews","date":"Updated March 15, 2018","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK1201/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":9141,"questionText":"Is neurofibromatosis type 2 inherited?","answerText":"Neurofibromatosis type 2 (NF2) is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002049.htm\" target=\"_blank\">autosomal dominant</a>&nbsp;pattern.[9354] All individuals inherit two copies of each gene. Autosomal means the gene is found on one of the numbered chromosomes found in both sexes. Dominant means that only one altered copy of a gene is necessary to have the condition. The alteration can be inherited from either parent. Sometimes an autosomal dominant condition occurs because of a new genetic alteration (de novo), and there is no history of this condition in the family. This happens in about half of the cases of NF2.[9354]<br />\r\n&nbsp;<br />\r\nEach child of an individual with an autosomal dominant condition has a 50% or 1 in 2 chance of inheriting the alteration and the condition. Typically, children who inherit a dominant alteration will have the condition, but they may be more or less severely affected than their parent. Sometimes a person may have a gene alteration for an autosomal dominant condition and show no signs or symptoms of the condition.&nbsp;<br />","dateModified":"2020-05-26T00:00:00","resourceClassificationName":"Inheritance","references":[{"referenceId":9354,"authors":"Evans DG","articleTitle":"Neurofibromatosis 2","bookWebsiteJournalTitle":"GeneReviews","date":"Updated March 15, 2018","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK1201/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":9142,"questionText":"How is neurofibromatosis type 2 diagnosed?","answerText":"The diagnosis of neurofibromatosis type 2 (NF2) is based on clinical exam, the symptoms, and imaging studies. Genetic testing for a change (<a href=\"https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/genetic-variant\" target=\"_blank\">variant</a>) in the <a href=\"http://ghr.nlm.nih.gov/gene/NF2\" target=\"_blank\"><em>NF2</em></a> gene may be helpful.[9354] Diagnostic criteria for this condition is available.[15596][15597]","dateModified":"2020-05-26T00:00:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":9354,"authors":"Evans DG","articleTitle":"Neurofibromatosis 2","bookWebsiteJournalTitle":"GeneReviews","date":"Updated March 15, 2018","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK1201/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":15596,"authors":"Smith MJ, Bowers NL, Bulman M, Gokhale C, Wallace AJ et al","articleTitle":"Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis [published correction appears in Neurology. 2017 Jul 11;89(2):215].","bookWebsiteJournalTitle":"Neurology. 2017;88(1):87-92.","date":"2017","volume":"88(1)","pages":"87-92","url":"https://pubmed.ncbi.nlm.nih.gov/27856782","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":15597,"authors":"Evans DG, King AT, Bowers NL, et al","articleTitle":"Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing.","bookWebsiteJournalTitle":"Genet Med. 2019;21(7):1525-1533.","date":"2019","volume":"21(7)","pages":"1525-1533","url":"https://pubmed.ncbi.nlm.nih.gov/30523344","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":9143,"questionText":"How might neurofibromatosis type 2 be treated?","answerText":"The treatment of neurofibromatosis type 2 (NF2) is based on managing the signs and symptoms present in each person. Surgery and gamma knife procedures may be used to treat and remove <a href=\"https://medlineplus.gov/acousticneuroma.html\" target=\"_blank\">vestibular schwannomas</a>.[15598] Other tumors associated with NF2 may also be treated surgically, although <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002324.htm\" target=\"_blank\">chemotherapy</a> and/or radiation therapy may also be recommended.[9354][9357]<br />\r\n<br />\r\nSpecialists involved in the care of someone with NF2 include:<br />\r\n<ul>\r\n    <li>Dermatologist</li>\r\n    <li>Neurologist</li>\r\n    <li>Otolaryngologist</li>\r\n    <li>Ophthmalogist</li>\r\n    <li>Audiologist</li>\r\n    <li>Oncologist</li>\r\n    <li>Medical geneticist</li>\r\n</ul>","dateModified":"2020-05-26T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":9354,"authors":"Evans DG","articleTitle":"Neurofibromatosis 2","bookWebsiteJournalTitle":"GeneReviews","date":"Updated March 15, 2018","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK1201/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9357,"authors":"Evans DG","articleTitle":"Neurofibromatosis type 2","bookWebsiteJournalTitle":"UpToDate","date":"April 2015","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":15598,"authors":"Lu VM, Ravindran K, Graffeo CS, et al","articleTitle":"Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes","bookWebsiteJournalTitle":"J Neurooncol","date":"2019","volume":"144(2)","pages":"239-248","url":"https://pubmed.ncbi.nlm.nih.gov/31254266","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[{"referenceId":15589,"authors":"Evans DG","articleTitle":"Neurofibromatosis 2","bookWebsiteJournalTitle":"GeneReviews","date":"Updated March 15, 2018","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK1201","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":15590,"authors":"Evans DG","articleTitle":"Neurofibromatosis type 2","bookWebsiteJournalTitle":"Handb Clin Neurol","date":"2015","volume":"132","pages":"87-96","url":"https://www.ncbi.nlm.nih.gov/pubmed/26564072","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":15592,"authors":"Slattery WH","articleTitle":"Neurofibromatosis type 2","bookWebsiteJournalTitle":"Otolaryngol Clin North Am","date":"Jun 2015","volume":"48(3)","pages":"443-60","url":"https://www.ncbi.nlm.nih.gov/pubmed/26043141","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9354,"authors":"Evans DG","articleTitle":"Neurofibromatosis 2","bookWebsiteJournalTitle":"GeneReviews","date":"Updated March 15, 2018","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK1201/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":15594,"authors":"Evans DG","articleTitle":"Neurofibromatosis type 2","bookWebsiteJournalTitle":"Handb Clin Neurol","date":"2015","volume":"132","pages":"87-96","url":"https://pubmed.ncbi.nlm.nih.gov/26564072","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":15593,"authors":"Ardern-Holmes S, Fisher G, North K","articleTitle":"Neurofibromatosis type 2: Presentation, Major Complications, and Management, with a focus on the pediatric age group","bookWebsiteJournalTitle":"J Child Neurol","date":"Jan 2017","volume":"32(1)","pages":"9-22","url":"https://www.ncbi.nlm.nih.gov/27655473","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":3762,"authors":"","articleTitle":"Neurofibromatosis type 2","bookWebsiteJournalTitle":"Genetics Home Reference","date":"Updated Dec 2013","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition/neurofibromatosis-type-2","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":15595,"authors":"Slattery WH","articleTitle":"Neurofibromatosis type 2","bookWebsiteJournalTitle":"Otolaryngol Clin North Am","date":"Jun 2015","volume":"48(3)","pages":"443-60","url":"https://pubmed.ncbi.nlm.nih.gov/26043141","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":15596,"authors":"Smith MJ, Bowers NL, Bulman M, Gokhale C, Wallace AJ et al","articleTitle":"Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis [published correction appears in Neurology. 2017 Jul 11;89(2):215].","bookWebsiteJournalTitle":"Neurology. 2017;88(1):87-92.","date":"2017","volume":"88(1)","pages":"87-92","url":"https://pubmed.ncbi.nlm.nih.gov/27856782","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":15597,"authors":"Evans DG, King AT, Bowers NL, et al","articleTitle":"Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing.","bookWebsiteJournalTitle":"Genet Med. 2019;21(7):1525-1533.","date":"2019","volume":"21(7)","pages":"1525-1533","url":"https://pubmed.ncbi.nlm.nih.gov/30523344","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":15598,"authors":"Lu VM, Ravindran K, Graffeo CS, et al","articleTitle":"Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes","bookWebsiteJournalTitle":"J Neurooncol","date":"2019","volume":"144(2)","pages":"239-248","url":"https://pubmed.ncbi.nlm.nih.gov/31254266","authors2":"","placeOfPublication":"","publisher":""}],"relatedDiseases":[{"relatedDiseaseId":10420,"relatedDiseaseName":"Neurofibromatosis","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":11991,"phenoTypeName":"Neuroma","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":9413,"phenoTypeName":"Abnormal cerebellum morphology","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":3159,"phenoTypeName":"Abnormal hand morphology","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13598,"phenoTypeName":"Babinski sign","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5835,"phenoTypeName":"Bilateral vestibular Schwannoma","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11728,"phenoTypeName":"Cognitive impairment","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13409,"phenoTypeName":"Constipation","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":14142,"phenoTypeName":"Delayed speech and language development","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13402,"phenoTypeName":"Dysphagia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11698,"phenoTypeName":"Dysuria","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9384,"phenoTypeName":"Generalized hypotonia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8723,"phenoTypeName":"Global developmental delay","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":933,"phenoTypeName":"Hyperesthesia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":10388,"phenoTypeName":"Hypertelorism","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":14292,"phenoTypeName":"Impaired vibratory sensation","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11451,"phenoTypeName":"Intracranial meningioma","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5679,"phenoTypeName":"Joint hypermobility","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8729,"phenoTypeName":"Motor delay","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13866,"phenoTypeName":"Myelopathy","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11162,"phenoTypeName":"Overbite","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5839,"phenoTypeName":"Peripheral Schwannoma","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8463,"phenoTypeName":"Posterior subcapsular cataract","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11337,"phenoTypeName":"Sensorineural hearing impairment","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":3605,"phenoTypeName":"Short stature","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5658,"phenoTypeName":"Slurred speech","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5224,"phenoTypeName":"Spastic dysarthria","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11407,"phenoTypeName":"Spastic paraparesis","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9417,"phenoTypeName":"Specific learning disability","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13165,"phenoTypeName":"Spinal cord tumor","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13597,"phenoTypeName":"Upper limb muscle weakness","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":3067,"phenoTypeName":"Abnormal thumb morphology","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":6101,"phenoTypeName":"Abnormality of the nares","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9172,"phenoTypeName":"Abnormality of the optic nerve","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10123,"phenoTypeName":"Amblyopia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4289,"phenoTypeName":"Ankle clonus","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":14132,"phenoTypeName":"Anxiety","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10089,"phenoTypeName":"Blindness","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5231,"phenoTypeName":"Brain stem compression","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":1208,"phenoTypeName":"Clinodactyly","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":11461,"phenoTypeName":"Cortical cataract","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10125,"phenoTypeName":"Diplopia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5271,"phenoTypeName":"Distal amyotrophy","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5603,"phenoTypeName":"Downslanted palpebral fissures","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8703,"phenoTypeName":"Dysarthria","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":6009,"phenoTypeName":"Emotional lability","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4299,"phenoTypeName":"Ependymoma","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9886,"phenoTypeName":"Epicanthus","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":11456,"phenoTypeName":"Epiretinal membrane","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":2766,"phenoTypeName":"Facial palsy","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":3466,"phenoTypeName":"Foot dorsiflexor weakness","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":7947,"phenoTypeName":"Genu valgum","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":14131,"phenoTypeName":"Hallucinations","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8728,"phenoTypeName":"Hemiparesis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4766,"phenoTypeName":"Hoarse voice","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9825,"phenoTypeName":"Hydrocephalus","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10277,"phenoTypeName":"Hyperpigmentation of the skin","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":11305,"phenoTypeName":"Low-set ears","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":11437,"phenoTypeName":"Memory impairment","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9844,"phenoTypeName":"Microcephaly","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":2231,"phenoTypeName":"Mononeuropathy","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5841,"phenoTypeName":"Occasional neurofibromas","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":11247,"phenoTypeName":"Panic attack","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":3896,"phenoTypeName":"Pes cavus","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8730,"phenoTypeName":"Polyneuropathy","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13848,"phenoTypeName":"Postural instability","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10382,"phenoTypeName":"Prominent nose","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":6006,"phenoTypeName":"Psychosis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5840,"phenoTypeName":"Retinal hamartoma","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8719,"phenoTypeName":"Seizure","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13594,"phenoTypeName":"Sensory impairment","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":11439,"phenoTypeName":"Sleep disturbance","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13452,"phenoTypeName":"Spastic gait","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":305,"phenoTypeName":"Speech apraxia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":11452,"phenoTypeName":"Spinal meningioma","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10434,"phenoTypeName":"Tinnitus","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":11410,"phenoTypeName":"Unsteady gait","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9162,"phenoTypeName":"Visual loss","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":7080,"phenoTypeName":"Wrist drop","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5157,"phenoTypeName":"Aphasia","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":5838,"phenoTypeName":"Astrocytoma","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":8720,"phenoTypeName":"Ataxia","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":10286,"phenoTypeName":"Cafe-au-lait spot","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":11303,"phenoTypeName":"Hearing impairment","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":10060,"phenoTypeName":"Hydronephrosis","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":8471,"phenoTypeName":"Juvenile posterior subcapsular lenticular opacities","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":7948,"phenoTypeName":"Meningioma","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":14409,"phenoTypeName":"Remnants of the hyaloid vascular system","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":5836,"phenoTypeName":"Unilateral vestibular Schwannoma","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":11411,"phenoTypeName":"Vertigo","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":6539,"phenoTypeName":"Autosomal dominant inheritance","percentRanges":"-"},{"phenoTypeId":11409,"phenoTypeName":"Headache","percentRanges":"-"},{"phenoTypeId":2230,"phenoTypeName":"Peripheral neuropathy","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Neurofibromatosis_type_2"}